These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24251953)

  • 1. Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension.
    Nickel NP; Lichtinghagen R; Golpon H; Olsson KM; Brand K; Welte T; Hoeper MM
    Respir Res; 2013 Nov; 14(1):130. PubMed ID: 24251953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension.
    Filusch A; Zelniker T; Baumgärtner C; Eschricht S; Frey N; Katus HA; Chorianopoulos E
    Clin Res Cardiol; 2011 Oct; 100(10):879-85. PubMed ID: 21479966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1.
    Silva Marques J; Martins SR; Calisto C; Gonçalves S; Almeida AG; de Sousa JC; Pinto FJ; Diogo AN
    J Heart Lung Transplant; 2013 Dec; 32(12):1214-21. PubMed ID: 23916896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
    Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
    Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis.
    Kerbert AJ; Verbeke L; Chiang FW; Laleman W; van der Reijden JJ; van Duijn W; Nevens F; Wolterbeek R; van Hoek B; Verspaget HW; Coenraad MJ
    PLoS One; 2015; 10(9):e0138264. PubMed ID: 26378453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of the N-terminal pro-brain-type natriuretic peptide response to exercise with disease severity in therapy-naive pulmonary arterial hypertension: a cohort study.
    Kutsch J; Faul C; von Scheidt W; Schwaiblmair M; Berghaus TM
    Respir Res; 2018 Jan; 19(1):8. PubMed ID: 29334941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
    Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
    Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.
    Takatsuki S; Wagner BD; Ivy DD
    Congenit Heart Dis; 2012; 7(3):259-67. PubMed ID: 22325151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease.
    Gaheen R; El Amrousy D; Hodeib H; Elnemr S
    Eur J Pediatr; 2021 Sep; 180(9):2889-2895. PubMed ID: 33813676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    JAMA; 2011 May; 305(20):2088-95. PubMed ID: 21610241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological serum markers in the management of pediatric pulmonary arterial hypertension.
    Van Albada ME; Loot FG; Fokkema R; Roofthooft MT; Berger RM
    Pediatr Res; 2008 Mar; 63(3):321-7. PubMed ID: 18287971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension.
    Calvier L; Legchenko E; Grimm L; Sallmon H; Hatch A; Plouffe BD; Schroeder C; Bauersachs J; Murthy SK; Hansmann G
    Heart; 2016 Mar; 102(5):390-6. PubMed ID: 26869635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension.
    Woods PR; Taylor BJ; Frantz RP; Johnson BD
    Am J Cardiol; 2012 Apr; 109(7):1066-72. PubMed ID: 22245407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copeptin reliably reflects longitudinal right ventricular function.
    Harbrücker M; Natale M; Kim SH; Müller J; Ansari U; Huseynov A; Zworowsky MV; Borggrefe M; Hoffmann U; Lang S; Fatar M; Roth T; Kittel M; Bertsch T; Akin I; Behnes M
    Ann Clin Biochem; 2021 Jul; 58(4):270-279. PubMed ID: 33430599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin.
    Hellenkamp K; Schwung J; Rossmann H; Kaeberich A; Wachter R; Hasenfuß G; Konstantinides S; Lankeit M
    Eur Respir J; 2015 Dec; 46(6):1701-10. PubMed ID: 26493800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.